Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.

scientific article published in January 2006

Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1460-9568.2005.04545.X
P698PubMed publication ID16420411
P5875ResearchGate publication ID7352987

P50authorMaria MorelloQ61134075
Vincenza D'AngeloQ38323218
Alessandro MartoranaQ45299885
P2093author name stringGiorgio Bernardi
Giuseppe Sancesario
Carmela Giampà
Francesca R Fusco
Zena DeMarch
P2860cites workCellular factors controlling neuronal vulnerability in the brain: a lesson from the striatumQ34090320
Transcriptional abnormalities in Huntington diseaseQ35113363
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectHuntington's diseaseQ190564
excitotoxicityQ901117
striatumQ1319792
P304page(s)11-20
P577publication date2006-01-01
P1433published inEuropean Journal of NeuroscienceQ5412733
P1476titleStriatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease
P478volume23

Reverse relations

cites work (P2860)
Q37345118A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease
Q37061555BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation.
Q37139004Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia
Q48093702Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry
Q52676144Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.
Q28748849Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease
Q38085375Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.
Q37750542Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease
Q92269192Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease
Q90439419Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences
Q28547107PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease
Q47732711Role of Phosphodiesterases in Huntington's Disease
Q38616832Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease
Q34017941Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice
Q28488296Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease
Q21092845The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease
Q41821958Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease

Search more.